Genentech, A Member of the Roche Group

Genentech, A Member of the Roche Group
Share
Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 35 years, using human genetic information to discover, develop, manufacture, and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, Genentech is among the world's leading biotech companies, with multiple products on the market and a promising development pipeline.

Data from pivotal Phase III study will be submitted to health authorities and presented at an upcoming medical meeting South San Francisco, CA -- September 18, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MURANO study, which evaluated Venclexta™ (venetoclax) in combination with...

South San Francisco, CA -- September 6, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), is voluntarily recalling three lots of Activase® (alteplase) 100mg vials, that were co-packaged with Sterile Water for Injection, to the hospital level. The vials of Sterile Water for Injection, manufactured by Hospira Inc., a Pfizer...

Actemra is the first FDA-approved treatment for severe or life-threatening cytokine release syndrome induced by CAR T cell therapy CAR T cell therapy is an immunotherapy designed for the treatment of certain cancers This is the seventh FDA approval for Actemra since its U.S. launch in 2010 South San Francisco, CA -- August 30, 2017 -- Genentech, a...

Application based on positive results of Phase III study in adults and adolescents with hemophilia A with inhibitors and interim Phase III results in children South San Francisco, CA -- August 23, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has...

South San Francisco, CA -- August 2, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review for Alecensa® (alectinib) as an initial (first-line) treatment for people...

HAVEN 1 showed emicizumab reduced bleed rate by 87 percent compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate by 79 percent compared to prior prophylactic bypassing agents Data from HAVEN 1 in adults and adolescents and interim...

Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented at the 26th International Society on Thrombosis and Haemostasis (ISTH) Meeting South San Francisco, CA -- June 25, 2017 -- Genentech, a member of...

Treatment can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan South San Francisco, CA -- June 22, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved RITUXAN HYCELA™ (rituximab and hyaluronidase human)...

On June 22, the FDA approved RITUXAN HYCELA™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and...

Second positive Phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa lowered the risk of tumor spread or growth in the brain or central nervous system Data will be simultaneously published in the New England Journal of Medicine and featured in the official ASCO press...